Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBlue Cross Blue Shield NM Allergen Testing Coverag…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - New MexicoPolicy RPLAB013

    Allergen Testing

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - New Mexico Policy RPLAB013 alerts

    Get alerted when Policy RPLAB013 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Blue Cross Blue Shield New Mexico's reimbursement stance and criteria for in‑vitro and skin allergen testing and related laboratory procedures for covered members and providers.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyAllergen Testing
    Policy CodePolicy RPLAB013
    Change TypeMaterial edits: added same-day exclusion, added CPT 95004, clarified exclusions
    Effective DateSep 4, 2026
    Last ReviewJun 15, 2025
    Next Review Date
    Key ActionSubmit accurate documentation and use valid code combinations; claims may require additional documentation on request.
    SourceLink
    POLICY UPDATE CHANGES

    When performed on the same day as skin prick testing, specific IgE in-vitro allergy testing is not reimbursable.

    Added CPT code 95004 to the policy coding list.

    For individuals with signs or symptoms of allergies, basophil activation flow cytometry testing and in‑vitro testing of IgG, IgA, IgM, and/or IgD are not reimbursable.

    A prior guidance-only Reimbursement Information item #1 was removed.

    up to 20annual reimbursable tests
    multipleexplicitly excluded tests
    1new reimbursement item added

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    listprocedure codes listed
    95004CPT code added

    Coverage Criteria and Exclusions

    Primary coverage criteria and exclusions

    Covered or excluded as specified below when billing for in‑vitro and related allergy testing:

    ALL of the following

    • ALL of the following

      • Testing is limited to allergens selected based on the individual’s history, physical examination, and environment.
      • Provider limits testing to no more than up to 20 allergen‑specific IgE antibody tests per year.
    • ANY of the following

      • Individual has moderate to severe asthma.
      • Individual has signs or symptoms of allergic bronchopulmonary aspergillosis.
    • ALL of the following

      • Annual re‑testing of the same food allergen(s) to monitor for allergy resolution is permitted when there was an initial positive food allergen result.

    ANY of the following

    • Specific IgE in‑vitro testing performed on the same day as skin prick testing.
    • Routine re‑testing for the same allergens in the absence of a new clinical presentation (except where specifically allowed above).
    • Antigen Leukocyte Antibody test / ALCAT.
    • Basophil activation flow cytometry testing for individuals with signs or symptoms of allergies.
    • In‑vitro testing of IgG, IgA, IgM, and/or IgD for individuals with signs or symptoms of allergies.
    • In‑vitro allergen testing using bead‑based epitope assays (e.g., VeriMAP Peanut Dx).

    Reimbursement exclusions and rules

    Operational reimbursement rules, recent edits, and combined exclusions:

    Note: References and policy history: changes described above are documented in the policy history (approval/edits dated 05/15/2026 and earlier).

    Procedure Codes and Limits

    Example procedure codes (not exhaustive)CPT
    82784ASSAY IGA/IGD/IGG/IGM EACH
    82785ASSAY OF IGE
    86005ALLG SPEC IGE MULTIALLG SCR
    95004PERCUT ALLERGY SKIN TESTS
    0165UPEANUT ALLG ASMT EPI PRB ALL
    Added codesCPTCovered
    95004Added to policy coding list
    inv-05: specific IgE annual limit
    Annual limitUp to 20 allergen-specific IgE antibody tests per year when allergens are selected based on the individual's history, physical examination, and environment.
    Selection basisAllergen selection must be driven by patient history, physical exam, and environmental exposure to qualify for the annual limit.
    Pediatric re-testing noteAnnual re-testing for the same food allergen(s) to monitor resolution in children and adolescents may be reimbursable (separate from the routine retesting exclusion).
    inv-06: same-day testing rule
    Same-day testing ruleSpecific IgE in‑vitro allergy testing is not reimbursable when performed on the same day as skin prick testing.
    Policy change

    Documentation, Billing, and Prior Authorization

    Documentation Required

    Documentation and claims coding: submit accurate documentation and use valid code sets

    Providers must submit accurate documentation of services performed and submit claims using valid code combinations from HIPAA-approved code sets. Claims should be coded according to industry standard coding guidelines (for example: Uniform Billing Editor, AMA CPT Assistant, HCPCS, ICD-10-CM/PCS, NDC, DRG guidelines, CMS NCCI Policy Manual, and CCI table edits). Claims are subject to code edit protocols and may be reviewed; upon request providers should submit additional documentation to support the claim.

    • Submit claims using valid code combinations from HIPAA-approved code sets.
    • Code claims per industry-standard guidelines (CPT, HCPCS, ICD-10, NCCI, CCI edits, etc.).
    • Be prepared to provide additional documentation upon request; claims are subject to code edit protocols and review.

    Key Definitions and Non-reimbursable Tests

    inv-09: In‑vitro testing for allergen-specific IgE antibodies
    DefinitionIn‑vitro testing for allergen-specific IgE antibodies refers to laboratory blood tests that measure IgE antibodies to selected allergens (specific IgE) to aid in diagnosing IgE‑mediated allergic disease.
    Reimbursable scopeSpecific IgE in‑vitro testing may be reimbursable when limited to allergens chosen based on an individual's history, physical examination, and environment.
    ExclusionsQualitative multi-allergen screens that do not identify specific allergens are not reimbursable; bead-based epitope assays (e.g., VeriMAP Peanut Dx) are not reimbursable.
    inv-10: Laboratory measurement of total IgE
    DefinitionTotal serum IgE testing measures overall immunoglobulin E in the blood (total IgE).
    Reimbursable indications
    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyAllergen Testing
    Policy CodePolicy RPLAB013
    Change TypeMaterial edits: added same-day exclusion, added CPT 95004, clarified exclusions
    Effective DateSep 4, 2026
    Last ReviewJun 15, 2025
    Next Review Date
    Key ActionSubmit accurate documentation and use valid code combinations; claims may require additional documentation on request.
    SourceLink
    On This Page
    Coverage Criteria and ExclusionsProcedure Codes and LimitsDocumentation, Billing, and Prior AuthorizationKey Definitions and Non-reimbursable Tests
    In‑vitro testing using qualitative specific IgE multi‑allergen screens that do not identify specific allergens.
    This same-day exclusion was added to the Reimbursement Information as new item #4 (documented in policy history).
    Coding implicationWhen both skin prick testing and in‑vitro specific IgE testing are performed on the same day, the in‑vitro test is not eligible for reimbursement; providers should bill accordingly.
    Billing Rule

    Prior authorization / reimbursement note: same‑day testing non‑reimbursement and CPT 95004 added

    Specific IgE in‑vitro allergy testing performed on the same day as skin prick testing is not reimbursable; additionally, CPT code 95004 was added to the policy coding list.

    • Do not bill for specific IgE in‑vitro allergy testing when it is performed the same day as skin prick testing—those in‑vitro tests are not reimbursable.
    • Note that CPT code 95004 (percutaneous allergy skin tests) was added to the policy coding list; verify appropriate use and coding when billing skin testing.
    May be reimbursable for individuals with moderate to severe asthma or for those with signs or symptoms of allergic bronchopulmonary aspergillosis.
    ContextTotal IgE testing is considered separately from specific IgE testing and is covered only for the specified clinical scenarios.
    inv-11: Non-reimbursable laboratory allergy tests
    Non-reimbursable tests (basophil activation)Basophil activation flow cytometry testing is not reimbursable for individuals with signs or symptoms of allergies.
    Non-reimbursable tests (immunoglobulins)In‑vitro testing of IgG, IgA, IgM, and/or IgD for individuals with signs or symptoms of allergies is not reimbursable.
    Other excluded assaysAntigen Leukocyte Antibody test/ALCAT and bead-based epitope assays (e.g., VeriMAP Peanut Dx) are not reimbursable.